Market Closed -
Nasdaq
04:00:00 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
6.1
USD
|
-3.02%
|
|
+0.83%
|
+36.77%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
189.9
|
1,559
|
534
|
216.4
|
491.6
|
944.8
|
-
|
-
|
Enterprise Value (EV)
1 |
189.9
|
1,380
|
421.2
|
168.1
|
491.6
|
944.8
|
944.8
|
944.8
|
P/E ratio
|
-2.07
x
|
-8.09
x
|
-77.4
x
|
-2.9
x
|
-4.42
x
|
-5.67
x
|
-6.97
x
|
-9.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
44.9
x
|
89.6
x
|
12.3
x
|
4.2
x
|
8.41
x
|
14.1
x
|
12
x
|
7.53
x
|
EV / Revenue
|
44.9
x
|
89.6
x
|
12.3
x
|
4.2
x
|
8.41
x
|
14.1
x
|
12
x
|
7.53
x
|
EV / EBITDA
|
-2.28
x
|
-25.9
x
|
-7.06
x
|
-2.83
x
|
-6.19
x
|
-8.07
x
|
0.69
x
|
-59.8
x
|
EV / FCF
|
-2.38
x
|
-28.7
x
|
-8
x
|
-3.42
x
|
-6.44
x
|
-8.15
x
|
-10.3
x
|
-14.1
x
|
FCF Yield
|
-42%
|
-3.49%
|
-12.5%
|
-29.3%
|
-15.5%
|
-12.3%
|
-9.68%
|
-7.09%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
48,080
|
75,302
|
76,610
|
77,010
|
110,219
|
154,889
|
-
|
-
|
Reference price
2 |
3.950
|
20.70
|
6.970
|
2.810
|
4.460
|
6.100
|
6.100
|
6.100
|
Announcement Date
|
3/12/20
|
3/11/21
|
2/28/22
|
3/6/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.227
|
17.4
|
43.52
|
51.49
|
58.44
|
66.97
|
78.82
|
125.5
|
EBITDA
1 |
-83.27
|
-60.07
|
-75.62
|
-76.54
|
-79.4
|
-117
|
1,375
|
-15.79
|
EBIT
1 |
-85.8
|
-62.85
|
-78.04
|
-78.65
|
-82.38
|
-124.9
|
-130.5
|
-103
|
Operating Margin
|
-2,029.86%
|
-361.13%
|
-179.3%
|
-152.74%
|
-140.96%
|
-186.57%
|
-165.62%
|
-82.04%
|
Earnings before Tax (EBT)
1 |
-86.37
|
-155.6
|
-6.553
|
-71.04
|
-80.74
|
-156.7
|
-129.4
|
-102.2
|
Net income
1 |
-86.37
|
-155.6
|
-6.553
|
-71.04
|
-80.74
|
-151.8
|
-129.5
|
-101.6
|
Net margin
|
-2,043.34%
|
-894.31%
|
-15.06%
|
-137.95%
|
-138.14%
|
-226.75%
|
-164.25%
|
-80.97%
|
EPS
2 |
-1.910
|
-2.560
|
-0.0900
|
-0.9700
|
-1.010
|
-1.076
|
-0.8757
|
-0.6680
|
Free Cash Flow
1 |
-79.82
|
-54.4
|
-66.74
|
-63.32
|
-76.32
|
-116
|
-91.5
|
-67
|
FCF margin
|
-1,888.24%
|
-312.56%
|
-153.36%
|
-122.96%
|
-130.59%
|
-173.22%
|
-116.09%
|
-53.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/11/21
|
2/28/22
|
3/6/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
12.31
|
13.19
|
12.27
|
11.96
|
14.08
|
13.37
|
15.19
|
15.08
|
14.8
|
14.77
|
16.03
|
16.89
|
19.21
|
18.49
|
18.83
|
EBITDA
1 |
-17.48
|
-17.28
|
-
|
-21.04
|
-18.87
|
-22.07
|
-19.92
|
-18.32
|
-
|
-30.7
|
-29.01
|
-28.37
|
-26.97
|
-25.82
|
-25.82
|
EBIT
1 |
-18.05
|
-17.83
|
-19.92
|
-21.54
|
-19.36
|
-22.55
|
-20.57
|
-19.21
|
-20.05
|
-31.62
|
-29.58
|
-30.92
|
-32.89
|
-23.03
|
-23.72
|
Operating Margin
|
-146.63%
|
-135.23%
|
-162.37%
|
-180.06%
|
-137.55%
|
-168.6%
|
-135.45%
|
-127.41%
|
-135.45%
|
-214%
|
-184.51%
|
-183.07%
|
-171.16%
|
-124.52%
|
-126.02%
|
Earnings before Tax (EBT)
1 |
-3.85
|
-12.54
|
-18.77
|
-24.19
|
-15.54
|
-30.32
|
-20.68
|
-0.516
|
-29.22
|
-64.85
|
-28.81
|
-30.18
|
-32.9
|
-23.21
|
-23.92
|
Net income
1 |
-3.85
|
-12.54
|
-18.77
|
-24.19
|
-15.54
|
-30.32
|
-20.68
|
-0.516
|
-29.22
|
-64.85
|
-29.24
|
-30.46
|
-32.12
|
-23.21
|
-23.92
|
Net margin
|
-31.28%
|
-95.11%
|
-152.99%
|
-202.16%
|
-110.41%
|
-226.69%
|
-136.19%
|
-3.42%
|
-197.41%
|
-438.93%
|
-182.38%
|
-180.32%
|
-167.17%
|
-125.51%
|
-127.06%
|
EPS
2 |
-0.0500
|
-0.1600
|
-0.2400
|
-0.3100
|
-0.2400
|
-0.3900
|
-0.2600
|
-0.0100
|
-0.3500
|
-0.4900
|
-0.2043
|
-0.2157
|
-0.2086
|
-0.1600
|
-0.1600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/7/22
|
3/6/23
|
5/8/23
|
8/7/23
|
11/7/23
|
3/11/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
179
|
113
|
48.3
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-79.8
|
-54.4
|
-66.7
|
-63.3
|
-76.3
|
-116
|
-91.5
|
-67
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-73%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-0.8200
|
0.0700
|
0.0900
|
-
|
Capex
1 |
2.24
|
0.84
|
1.19
|
3.72
|
6.09
|
6.48
|
6.48
|
6.48
|
Capex / Sales
|
52.95%
|
4.83%
|
2.74%
|
7.21%
|
10.42%
|
9.68%
|
8.22%
|
5.16%
|
Announcement Date
|
3/12/20
|
3/11/21
|
2/28/22
|
3/6/23
|
3/11/24
|
-
|
-
|
-
|
Average target price
14.5
USD Spread / Average Target +137.70% Consensus |
1st Jan change
|
Capi.
|
---|
| +36.77% | 945M | | +37.78% | 723B | | +31.40% | 598B | | -3.51% | 364B | | +19.94% | 331B | | +5.14% | 288B | | +16.47% | 244B | | -4.62% | 208B | | +10.14% | 210B | | +9.32% | 169B |
Other Pharmaceuticals
|